Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8741866 Compositions and methods for inhibiting expression of transthyretin

Patent 8741866 was granted and assigned to Alnylam Pharmaceuticals on June, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

Alnylam Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Dinah Wen-Yee Sah0

Gregory Hinkle0

Qingmin Chen0

Rene Alvarez0

Stuart Milstein0

Date of Patent

June 3, 2014

0

Patent Application Number

134102620

Date Filed

March 1, 2012

0

Patent Citations Received

US Patent 11865190 Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto

0

0

US Patent 11980673 Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto

0

US Patent 11697812 Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA

0

US Patent 11959081 Transthyretin (TTR) iRNA compositions and methods of use thereof

0

Patent Primary Examiner

0

Patent abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8741866 Compositions and methods for inhibiting expression of transthyretin

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool